Compositions and methods for treating phenylketonuria
US-2024141381-A1 · May 2, 2024 · US
Anti-cancer agent comprising HVJ-E and CXCL2
US10441613B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10441613-B2 |
| Application number | US-201615754687-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 23, 2016 |
| Priority date | Aug 24, 2015 |
| Publication date | Oct 15, 2019 |
| Grant date | Oct 15, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides, as a new anti-cancer agent obtained by combining HVJ-E and a molecule synergistically acting therewith, an anti-cancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the prophylaxis or treatment of cancer, comprising administering an effective amount of a pharmaceutical composition comprising the following (1) and (2) to a subject: (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) CXCL2 or a nucleic acid comprising a base sequence encoding CXCL2. 2. A method of inducing an N1 type neutrophil, comprising administering an effective amount a pharmaceutical composition comprising the following (1) and (2) to a subject: (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) CXCL2 or a nucleic acid comprising a base sequence encoding CXCL2. 3. The method according to claim 1 , wherein the cancer is selected from the group consisting of melanoma, lung cancer, mesothelioma, tongue cancer, esophagus cancer, gastric cancer, liver cancer, large intestine cancer, prostate cancer, kidney cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor, thyroid cancer, angiosarcoma, osteosarcoma, chondrosarcoma, rhabdomyosarcoma and leiomyosarcoma. 4. The method according to claim 1 , wherein the nucleic acid comprising the base sequence encoding CXCL2 is an expression vector comprising a base sequence encoding CXCL2. 5. The method according to claim 4 , wherein the cancer is selected from the group consisting of melanoma, lung cancer, mesothelioma, tongue cancer, esophagus cancer, gastric cancer, liver cancer, large intestine cancer, prostate cancer, kidney cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor, thyroid cancer, angiosarcoma, osteosarcoma, chondrosarcoma, rhabdomyosarcoma and leiomyosarcoma. 6. The method according to claim 4 , wherein the nucleic acid comprising a base sequence encoding CXCL2 is encapsulated in HVJ-E. 7. The method according to claim 6 , wherein the cancer is selected from the group consisting of melanoma, lung cancer, mesothelioma, tongue cancer, esophagus cancer, gastric cancer, liver cancer, large intestine cancer, prostate cancer, kidney cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor, thyroid cancer, angiosarcoma, osteosarcoma, chondrosarcoma, rhabdomyosarcoma and leiomyosarcoma. 8. The method according to claim 1 , wherein the nucleic acid comprising a base sequence encoding CXCL2 is encapsulated in HVJ-E. 9. The method according to claim 8 , wherein the cancer is selected from the group consisting of melanoma, lung cancer, mesothelioma, tongue cancer, esophagus cancer, gastric cancer, liver cancer, large intestine cancer, prostate cancer, kidney cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor, thyroid cancer, angiosarcoma, osteosarcoma, chondrosarcoma, rhabdomyosarcoma and leiomyosarcoma. 10. The method according to claim 2 , wherein the nucleic acid comprising a base sequence encoding CXCL2 is an expression vector comprising a base sequence encoding CXCL2. 11. The method according to claim 10 , wherein the nucleic acid comprising a base sequence encoding CXCL2 is encapsulated in HVJ-E. 12. The method according to claim 2 , wherein the nucleic acid comprising a base sequence encoding CXCL2 is encapsulated in HVJ-E.
Assignees
Inventors
Classifications
Chemokines, e.g. RANTES · CPC title
- A61K35/76Primary
Viruses; Subviral particles; Bacteriophages · CPC title
Double-stranded nucleic acids or oligonucleotides · CPC title
Lipopolysaccharides · CPC title
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10441613B2 cover?
- The present invention provides, as a new anti-cancer agent obtained by combining HVJ-E and a molecule synergistically acting therewith, an anti-cancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.
- Who is the assignee on this patent?
- Univ Osaka, Genomidea Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K35/76. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).